STA
RARE icon

Summit Trail Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Summit Trail Advisors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$349K Buy
16,640
+2,301
+16% +$51.8K 0.01% 1271
2025
Q4 		$330K Buy
14,339
+5,497
+62% +$181K 0.01% 1190
2025
Q3 		$266K Buy
+8,842
New +$265K ﹤0.01% 1231
2018
Q1 		– Sell
-16
Closed -$1K – 1366
2017
Q4 		$1K Buy
+16
New +$785 ﹤0.01% 1845

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Summit Trail Advisors's RARE Position: Q1 2026 in Review

Summit Trail Advisors increased its Ultragenyx Pharmaceutical (RARE) stake by 16% in Q1 2026, buying an estimated $51.8K and bringing the position to 16,640 shares worth $349K. The position accounts for 0.01% of the portfolio, ranked #1271.

Summit Trail Advisors first reported a position in RARE in Q4 2017 and has held it in 4 quarters since. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Summit Trail Advisors held 16,640 shares of Ultragenyx Pharmaceutical worth $349K as of Q1 2026.
  • Summit Trail Advisors bought 2,301 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $51.8K.
  • Ultragenyx Pharmaceutical made up 0.01% of Summit Trail Advisors's portfolio in Q1 2026, its #1271 holding.
  • Summit Trail Advisors first reported a position in Ultragenyx Pharmaceutical in Q4 2017 and has held it in 4 quarters since.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Summit Trail Advisors's 13F filing for Q1 2026, filed 12 May 2026.